Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>BullFrog AI Holdings, Inc. (NASDAQ: BFRG) uses artificial intelligence (AI) to increase the success rate of drug development while reducing the time and investment it requires. </li><li>Based in Gaithersburg, MD and public since February 2023, the company was founded in 2017 by Vin Singh, who earlier co-founded the life sciences firm MaxCyte, Inc. (NASDAQ: MXCT). </li><li>BullFrog addresses a significant challenge in drug development: bringing a new drug to market typically requires 10-15 years and $1-2 billion in investment, yet many late-stage programs still fail.</li></ul>

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) uses artificial intelligence (AI) to increase the success rate of drug development while reducing the time and investment it requires. Based in Gaithersburg, MD and public since February 2023, the company was founded in 2017 by Vin Singh, who earlier co-founded the life sciences firm MaxCyte, Inc. (NASDAQ: MXCT). BullFrog addresses a significant challenge in drug development: bringing a new drug to market typically requires 10-15 years and $1-2 billion in investment, yet many late-stage programs still fail.

BFRG: Initiating Coverage; Helping Big Pharma Look Before It Leaps in Drug Discovery

Bullfrog AI Holdings

BFRG: Initiating Coverage; Helping Big Pharma Look Before It Leaps in Drug Discovery